FETUB and metabolic dysfunction-associated steatotic liver disease: These findings, therefore, provide a rationale for evaluating fetuin-A and fetuin-B in the pathophysiological process of NAFLD, and might open up new perspectives in early diagnosis, identification of novel biomarkers, and providing novel targets for pharmacological interventions.